{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:36:08Z","timestamp":1753893368825,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>A 9-year-old male neutered Cockapoo was presented with an acute and progressive history of exercise induced weakness involving all limbs, and bilateral decreased ability to blink. Investigations revealed generalized myasthenia gravis alongside the presence of a thymoma and a cholangiocellular carcinoma. Symptomatic treatment through pyridostigmine bromide was used to control clinical signs, and complete surgical removal of the thymoma and cholangiocellular carcinoma was performed. Serum acetylcholine receptor antibody concentration was measured serially. Clinical remission defined as resolution of clinical signs alongside discontinuation of treatment was achieved by day 251 (8.2 months). Immune remission defined as normalization of serum acetylcholine receptor antibody concentration alongside resolution of clinical signs and discontinuation of treatment was achieved by day 566 (18.5 months). Neurological examination was normal, and the owners did not report any clinical deterioration during the final follow-up appointment on day 752 (24 months), hence outcome was considered excellent. This is the first report describing the temporal evolution of serum acetylcholine receptor antibody concentration in a dog with thymoma-associated myasthenia gravis which achieved immune remission following thymectomy. Treatment was successfully discontinued without any evidence of clinical deterioration thereafter despite serum acetylcholine receptor antibody concentration not normalizing for another 315 days (10 months).<\/jats:p>","DOI":"10.3389\/fvets.2023.1124702","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:40:43Z","timestamp":1679028043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Immune remission from generalized myasthenia gravis in a dog with a thymoma and cholangiocellular carcinoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Thomas","family":"Mignan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Stee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Targett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lowrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/jvim.15855","article-title":"Classification of myasthenia gravis and congenital myasthenic syndromes in dogs and cats","volume":"34","author":"Mignan","year":"2020","journal-title":"J Vet Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/vetsci9070318","article-title":"Seronegative myasthenia gravis with concomitant SARS-CoV-2 infection in a dog","volume":"9","author":"Musteata","year":"2022","journal-title":"Vet Sci."},{"key":"B3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2460\/javma.1997.211.11.1428","article-title":"Risk factors for acquired myasthenia gravis in dogs: 1154 cases (1991-1995)","volume":"211","author":"Shelton","year":"1997","journal-title":"J Am Vet Med Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1111\/jvim.16223","article-title":"Clinical features and outcome of acquired myasthenia gravis in 94 dogs","volume":"35","author":"Forgash","year":"2021","journal-title":"J Vet Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/cen3.12319","article-title":"Role of the thymus in autoimmune myasthenia gravis","author":"Berrih-Aknin","year":"2016","journal-title":"Clin Exp Neuroimmunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.expneurol.2015.02.010","article-title":"Thymoma related myasthenia gravis in humans and potential animal models","volume":"270","author":"Marx","year":"2015","journal-title":"Exp Neurol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2460\/javma.1990.197.04.488","article-title":"Acquired myasthenia gravis and chollangiocellular carcinoma in a dog","volume":"197","author":"Krotje","year":"1990","journal-title":"J Am Vet Med Assoc."},{"key":"B8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2460\/javma.1990.197.02.225","article-title":"Osteogenic sarcoma and myasthenia gravis in a dog","volume":"197","author":"Moore","year":"1990","journal-title":"J Am Vet Med Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/089875641102800405","article-title":"Acquired myasthenia gravis associated with oral sarcoma in a dog","volume":"28","author":"Stepaniuk","year":"2011","journal-title":"J Vet Dent."},{"key":"B10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1748-5827.2000.tb03216.x","article-title":"Myasthenia gravis associated with cutaneous lymphoma in a dog","volume":"41","author":"Ridyard","year":"2000","journal-title":"J Small Anim Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1751-0813.2003.tb12883.x","article-title":"Acquired myasthenia gravis associated with a non-invasive thymic carcinoma in a dog","volume":"81","author":"Stenner","year":"2003","journal-title":"Aust Vet J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1748-5827.1998.tb03734.x","article-title":"Myasthenia gravis: lessons from the past 10 years","volume":"39","author":"Shelton","year":"1998","journal-title":"J Small Anim Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1053\/j.semtcvs.2016.04.002","article-title":"Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases","volume":"28","author":"Kaufman","year":"2016","journal-title":"Semin Thorac Cardiovasc Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0195-5616(03)00085-8","article-title":"Myasthenia gravis and disorders of neuromuscular transmission","volume":"32","author":"Shelton","year":"2002","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1748-5827.1996.tb02419.x","article-title":"Treatment of acquired myasthenia gravis associated with thymoma in two dogs","volume":"37","author":"Rusbridge","year":"1996","journal-title":"J Small Anim Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2460\/javma.243.10.1448","article-title":"Clinical features, treatment options, and outcome in dogs with thymoma: 116 cases (1999\u20132010)","volume":"243","author":"Robat","year":"2013","journal-title":"J Am Vet Med Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.3390\/ani11123444","article-title":"Canine epithelial thymic tumours. Oucome in 28 dogs treated by surgery","volume":"11","author":"Martano","year":"2021","journal-title":"Animals (Basel)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/WNL.57.11.2139","article-title":"Spontaneous remission in canine myasthenia gravis: implications for assessing human MG therapies","volume":"57","author":"Shelton","year":"2001","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0195-5616(03)00079-2","article-title":"Electrophysiology in neuromuscular disease","volume":"32","author":"Cuddon","year":"2002","journal-title":"Vet Clin North Am Small Anim Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity."},{"key":"B21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbi.2006.10.001","article-title":"Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue","volume":"21","author":"Galin","year":"2007","journal-title":"Brain Behav Immun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1600-0404.1994.tb02680.x","article-title":"Exacerbation of myasthenia gravis after removal of thymomas","volume":"90","author":"Somnier","year":"1994","journal-title":"Acta Neurol Scand."},{"key":"B23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1476-4431.2011.00636.x","article-title":"Myasthenia gravis in dogs with an emphasis on treatment and critical care management","volume":"21","author":"Khorzad","year":"2011","journal-title":"J Vet Emerg Crit Care (San Antonio)."},{"key":"B24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig."},{"key":"B25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/030098588101800403","article-title":"Canine bile duct carcinoma","volume":"18","author":"Patnaik","year":"1981","journal-title":"Vet Pathol."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2023.1124702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:27:43Z","timestamp":1729092463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2023.1124702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":25,"alternative-id":["10.3389\/fvets.2023.1124702"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2023.1124702","relation":{},"ISSN":["2297-1769"],"issn-type":[{"type":"electronic","value":"2297-1769"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"article-number":"1124702"}}